Bristol-Myers Squibb’s ORENCIA® (abatacept) Receives Second European Commission Approval in Less than a Year – New Approval for Treatment of Active Psoriatic Arthritis (PsA)1
Go back to Bristol-Myers Squibb’s ORENCIA® (abatacept) Receives Second European Commission Approval in Less than a Year – New Approval for Treatment of Active Psoriatic Arthritis (PsA)1| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 65.06 -1.76 (2.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.82 | 52 Week High | $77.12 | |||
| Open | $65.66 | 52 Week Low | $49.03 | |||
| Day High | $65.89 | P/E | 42.25 | |||
| Day Low | $64.40 | EPS | $1.54 | |||
| Volume | 3,478,687 | |||||
